MannKind Corporation Reports 43% Revenue Growth to $109.4 Million in Q2 2026

MannKind Corporation reported significant financial results for the second quarter of 2026, with total revenues reaching $109.4 million, a 43% increase from $76.5 million in the same period of 2025. The growth was driven by a substantial rise in commercial product sales, which amounted to $42.0 million, up 87% from $22.5 million year-over-year. Collaborations and services revenue also saw a notable increase, rising 53% to $35.0 million, while royalties from United Therapeutics increased by 4% to $32.4 million. However, the company recorded a net loss of $19.0 million, compared to a net income of $0.7 million in the prior year, reflecting increased operational costs and interest expenses.

In terms of expenses, MannKind's total costs rose to $109.7 million, a 54% increase from $71.2 million in the previous year. The cost of goods sold for commercial products surged by 213% to $14.4 million, primarily due to the addition of Furoscix to the product portfolio following the acquisition of scPharma. Research and development expenses also increased by 32% to $18.0 million, driven by ongoing development activities for Furoscix and other pipeline products. Selling, general, and administrative expenses nearly doubled to $58.3 million, reflecting costs associated with the promotion of Furoscix and the expansion of field-based teams.

Operationally, MannKind's product adoption rates varied, with Afrezza sales experiencing a decline of 6% in gross revenue due to lower demand, while Furoscix generated $31.1 million in gross revenue in its first year of commercialization. The company also reported a gross margin of 66% for commercial products, down from 79% in the previous year, attributed to the lower margin profile of Furoscix compared to Afrezza. The company’s cash and cash equivalents stood at $52.9 million as of June 30, 2026, down from $74.9 million at the end of 2025, reflecting cash used in operations and financing activities.

Looking ahead, MannKind remains focused on expanding its product offerings and enhancing its market presence. The company is actively pursuing opportunities for geographic expansion, particularly in India, where it has begun supplying Afrezza to its partner Cipla. Additionally, the company is advancing its pipeline, including the development of MNKD-201 for idiopathic pulmonary fibrosis and exploring the feasibility of a dry-powder formulation of bumetanide. MannKind's management believes that its current resources, combined with anticipated revenue from product sales and collaborations, will support its operational needs over the next 12 months.